Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells

Cancer Gene Therapy

Volumn 5, Issue 3, 1998, Pages 163-175

  Couderc, Bettina ^a   Zitvogel, Laurence ^a,b   Douin Echinard, Victorine ^a   Djennane, Leila ^a   Tahara, Hideaki ^b   Favre, Gilles ^a   Lotze, Michael T ^b   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

CD70; Costimulatory molecules; Gene therapy; IL 12; Tumorigenesis

Indexed keywords

CANCER VACCINE; CD40 LIGAND; CD70 ANTIGEN; INTERLEUKIN 12; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PRIMER DNA; TNFSF7 PROTEIN, HUMAN; TNFSF7 PROTEIN, MOUSE;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL STRAIN 3T3; EXPERIMENTAL NEOPLASM; GENE FREQUENCY; GENE VECTOR; GENETICS; IMMUNOLOGY; MOUSE; NUCLEOTIDE SEQUENCE; RETROVIRUS; SPLEEN;

3T3 CELLS; ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; ANTIGENS, CD70; BASE SEQUENCE; CANCER VACCINES; CD40 LIGAND; DNA PRIMERS; GENE FREQUENCY; GENETIC VECTORS; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; RETROVIRIDAE; SPLEEN; TUMOR CELLS, CULTURED;

EID: 0032066764     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180:1-4.
2. Boon T, Cerottini J, Van den Eynde B, Van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337-365.
3. Hellstrom KE, Hellstrom I. Principles of tumor immunity: tumor antigens. In: De Vita VT, Jr., Hellman S., Rosenberg S.A., eds. The Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott Company);1991:35-52.
4. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
5. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
6. Tepper RL, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57: 503-512.
7. Fearon ER, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons JW, Karasuyama H, Volgestein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an immune response. Cell. 1990;60:397-403.
8. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
9. Golumbek P, Lazenby A, Levitsky H, Jaffee E, Karasuyama H, Baker M, Pardoll D. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
10. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific and long lasting immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
11. Tahara H, Zeh HJ, III, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins P, Lotze MT. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
12. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immimol. 1995;155:1393-1403.
13. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chang S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
14. Stern AS, Podlaski FJ, Hulmes JD, Pan YCE, Quinn PM, Wolizky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, Gately MK. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
15. γ production in established Th2 cell clones. J Exp Med. 1994;179:1273-1283.
16. γ production by NKSF: characterisation of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869-879.
17. γ production. J Immunol 1994;153:1697-1706.
18. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, III, McKinney TG, Schreiber RD, Gubler U, Robbins P, Lotze MT. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
19. Schwartz RH. Acquisition of immunological self-tolerance. Cell. 1989;57:1073-1081.
20. Liu Y, Linsley PS. Costimulation of T cell growth. Curr Opin Immunol. 1992;4:265-270.
21. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA. 1993;90:6586-6590.
22. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11:191-212.
23. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994;15: 321-331.
24. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, and June CH. CD28 activation pathway regulates the production of multiple T-cell derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989;86:1333-1337.
25. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today. 1993;14:483-486.
26. Iezzi G, Protti MP, Rugarli C, Bellone M. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res. 1996;56:11-15.
27. Brunda MJ, Luistro L, Warrier LL, Wright RB, Hubbart BR, Murphy M, Wolf SF, Gately MK. Anti-tumor and anti-metastatic activity of IL-12 against murine tumors. J Exp Med. 1993;178:1223-1230.
28. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL. CD80 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 1995;55:4980-4987.
29. Hintzen RQ, Lens SM, Beckmann P, Goodwin RG, Lynch D, Van Lier RAW. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol. 1994;152:1762-1772.
30. Alderson MR. Regulation of immune responses by the ligands for CD27, CD30 and 4-1BB. Circ Shock. 1995;44: 73-76.
31. Banchereau J, Bazan F, Blanchard D, Briere JP, van Kooten C, Liu YJ, Rousset F, Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
32. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, Vandenbos T, Jerzy R, Tough TW, Schoenborn M, Davis-Smith T, Hennen K, Falk B, Cosman D, Baker E, Sutherland GR, Grabstein KH, Farrah T, Giri JG, Beckmann MP. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell. 1993;73:447-456.
33. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994;6: 407-413.
34. Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther. 1995;1: 75-105.
35. + naive T cell costimulation. J Immunol. 1994;153:5422-5432.
36. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol. 1995;154:4996-5010.
37. Nishioka Y, Lipsky PE. The role of CD40-CD154 interaction in human T cell-B cell collaboration. J Immunol. 1994;153:1027-1036.
38. Jumper MD, Nishioka Y, Davis LS, Lipsky PE, Meek K. Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J Immunol. 1995;155:2369-2378.
39. Jung W, Krueger S, Renner C, Gause A, Sahin U, Rumper L, Pfreundschuh M. Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol. 1994;31:1329-1334.
40. Agematsu K, Kobata T, Sugita K, Freeman GJ, Beckmann MP, Schlossman SF, Morimoto C. Role of CD27 in T cell immune response. J Immunol. 1994;153:1421-1429.
41. Hintzen RQ, Lens SMA, Lammers K, Kuiper H, Beckmann MP, Van Lier RAW. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol. 1995;154:2612-2623.
42. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
43. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT. CD80 costimulation markedly enhances IL-12-mediated antitumor immunity in vivo. Eur J Immunol. 1996;26:1335-1341.
44. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, A Laboratory Manual, 2nd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
45. Seronie-Vivien S, Pradines A, Couderc B, Clamagirand C, Berg D, Soula G, Favre G. Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA. Cell Growth Differ. 1995;6: 1415-1425.
46. + naive T cell costimulation. J Immunol. 1996;153:5422-5432.
47. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273:1862-1864.